{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:28:01Z","timestamp":1784366881023,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210077"],"award-info":[{"award-number":["JP21fk0210077"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210047"],"award-info":[{"award-number":["JP21fk0210047"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fk0210058"],"award-info":[{"award-number":["JP21fk0210058"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["JP21K15944"],"award-info":[{"award-number":["JP21K15944"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12328-021-01499-z","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T14:04:15Z","timestamp":1629468255000},"page":"1692-1699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer"],"prefix":"10.1007","volume":"14","author":[{"given":"Kazuya","family":"Ofuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-3555","authenticated-orcid":false,"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"1499_CR2","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"1499_CR3","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212\u20138.","journal-title":"Nat Immunol"},{"key":"1499_CR4","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","volume":"33","author":"JS Weber","year":"2015","unstructured":"Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092\u20139.","journal-title":"J Clin Oncol"},{"key":"1499_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"1499_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"issue":"13","key":"1499_CR7","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1073\/pnas.1611421113","volume":"1","author":"SK Subudhi","year":"2016","unstructured":"Subudhi SK, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA. 2016;1(13):11919\u201324.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1499_CR8","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","volume":"77","author":"DY Oh","year":"2017","unstructured":"Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017;77:1322\u201330.","journal-title":"Cancer Res"},{"key":"1499_CR9","first-page":"e8613","volume":"12","author":"A Pagan","year":"2020","unstructured":"Pagan A, Arroyo-Martinez YM, Tandon A, et al. Immune checkpoint inhibitor-induced acute pancreatitis and colitis. Cureus. 2020;12:e8613.","journal-title":"Cureus"},{"key":"1499_CR10","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","volume":"58","author":"AM Di Giacomo","year":"2009","unstructured":"Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58:1297\u2013306.","journal-title":"Cancer Immunol Immunother"},{"key":"1499_CR11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2217\/imt.15.87","volume":"7","author":"O Abdel-Rahman","year":"2015","unstructured":"Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015;7:1213\u201327.","journal-title":"Immunotherapy"},{"key":"1499_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","volume":"12","author":"C Prieux-Klotz","year":"2017","unstructured":"Prieux-Klotz C, Dior M, Damotte D, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12:301\u20138.","journal-title":"Target Oncol"},{"key":"1499_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol. 2018;71:665\u201371.","journal-title":"J Clin Pathol"},{"key":"1499_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","volume":"472","author":"N Assarzadegan","year":"2018","unstructured":"Assarzadegan N, Montgomery E, Anders RA. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch. 2018;472:125\u201333.","journal-title":"Virchows Arch"},{"key":"1499_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","volume":"31","author":"A Ribas","year":"2013","unstructured":"Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616\u201322.","journal-title":"J Clin Oncol"},{"key":"1499_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"1499_CR17","doi-asserted-by":"publisher","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","volume":"131","author":"JP Das","year":"2020","unstructured":"Das JP, Postow MA, Friedman CF, et al. Imaging findings of immune checkpoint inhibitor associated pancreatitis. Eur J Radiol. 2020;131:109250.","journal-title":"Eur J Radiol"},{"key":"1499_CR18","doi-asserted-by":"publisher","first-page":"243360","DOI":"10.1136\/bcr-2021-243360","volume":"14","author":"T Suda","year":"2021","unstructured":"Suda T, Kobayashi M, Kurokawa K, et al. Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab. BMJ Case Rep. 2021;14:243360.","journal-title":"BMJ Case Rep"},{"key":"1499_CR19","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jgh.13171","volume":"31","author":"YT Chen","year":"2016","unstructured":"Chen YT, Su JS, Tseng CW, et al. Inflammatory bowel disease on the risk of acute pancreatitis: a population-based cohort study. J Gastroenterol Hepatol. 2016;31:782\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1499_CR20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/MPA.0b013e3182258a15","volume":"40","author":"T Kamisawa","year":"2011","unstructured":"Kamisawa T, Chari ST, Giday SA, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40:809\u201314.","journal-title":"Pancreas"},{"key":"1499_CR21","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.3748\/wjg.v23.i19.3505","volume":"23","author":"JW Kim","year":"2017","unstructured":"Kim JW, Hwang SW, Park SH, et al. Clinical course of ulcerative colitis patients who develop acute pancreatitis. World J Gastroenterol. 2017;23:3505\u201312.","journal-title":"World J Gastroenterol"},{"key":"1499_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1097\/PAS.0000000000000891","volume":"41","author":"Y Ku","year":"2017","unstructured":"Ku Y, Hong SM, Fujikura K, et al. IL-8 expression in granulocytic epithelial lesions of idiopathic duct-centric pancreatitis (type 2 autoimmune pancreatitis). Am J Surg Pathol. 2017;41:1129\u201338.","journal-title":"Am J Surg Pathol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01499-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T16:10:05Z","timestamp":1635610205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01499-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"Informed consent was obtained from the patient included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}